



25 August 2023

Release of Restricted Securities from Escrow

In accordance with ASX Listing Rule 3.10A, PharmAust Limited (ASX: PAA & PAAO) advises that 562,557 ordinary shares will be released from voluntary escrow on 4 September 2023.

This announcement is authorised by Sam Wright on behalf of the Board of Directors.

Enquiries:

Dr Roger Aston

Executive Chairman

investorenquiries@pharmaust.com

P +61 (8) 9202 6814

F +61 (8) 9467 6111

www.pharmaust.com



About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.